Hologic - HOLX Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HOLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HOLX, but not buy additional shares or sell existing shares.
View HOLX analyst ratings or view top-rated stocks.

10 brokers have issued twelve-month price objectives for Hologic's stock. Their HOLX share price forecasts range from $70.00 to $85.00. On average, they predict the company's stock price to reach $76.71 in the next twelve months. This suggests a possible upside of 18.9% from the stock's current price.
View analysts price targets for HOLX or view top-rated stocks among Wall Street analysts.

Hologic's stock was trading at $76.56 at the beginning of 2022. Since then, HOLX stock has decreased by 15.7% and is now trading at $64.52.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our HOLX earnings forecast.

Hologic, Inc. (NASDAQ:HOLX) released its earnings results on Wednesday, July, 27th. The medical equipment provider reported $0.95 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.26. The medical equipment provider had revenue of $1 billion for the quarter, compared to analysts' expectations of $896.71 million. Hologic had a trailing twelve-month return on equity of 37.48% and a net margin of 28.93%. Hologic's quarterly revenue was down 14.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.33 earnings per share.
Read the conference call transcript.

Hologic issued an update on its fourth quarter 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $0.60-$0.65 for the period, compared to the consensus earnings per share estimate of $0.61. The company issued revenue guidance of $840.00 million-$870.00 million, compared to the consensus revenue estimate of $869.95 million.

447 employees have rated Hologic Chief Executive Officer Steve MacMillan on Glassdoor.com. Steve MacMillan has an approval rating of 79% among the company's employees. 81.0% of employees surveyed would recommend working at Hologic to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), Walt Disney (DIS), PayPal (PYPL), Advanced Micro Devices (AMD), CVS Health (CVS), Pfizer (PFE) and Abbott Laboratories (ABT).

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Shares of HOLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HOLX stock can currently be purchased for approximately $64.52.

Hologic (NASDAQ:HOLX) has a market capitalization of $16.11 billion and generates $5.63 billion in revenue each year. The medical equipment provider earns $1.87 billion in net income (profit) each year or $5.93 on an earnings per share basis.

The company employs 6,705 workers across the globe.

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The official website for the company is www.hologic.com. The medical equipment provider can be reached via phone at (508) 263-2900, via email at michael.watts@hologic.com, or via fax at 781-890-8031.